Decreased platelet sensitivity to anti-platelet agents is still unsolved clinical problem in cardiovascular disease. In this project, we propose a new approach for anti-platelet strategy focused on a purinergic pathway and involving an activation of adenosine P1 receptors (AR: A2A and A2B) with a simultaneous low-dose inhibition of classical (P2Y) purinergic ADP receptors. The project will involve a screening phase and post-screening tests of ligands’ action on human and animal blood platelets, cultured endothelial cells and in animal models of human pathology. Research TEAM supported in the Project will involve 3 young doctors, 4 PhD students and one senior researcher. The main outcome of the project will be the proof of concept for an innovative dual antiplatelet therapy, as well as candidate molecules tested in experiments with animals. The substances developed during the project implementation will be the subject for patent applications. Project fits nicely KIS1-I and KIS2-VIII.